mRNA Therapeutics Market Outlook report points to expanding oncology and rare-disease pipelines through 2035, with Moderna among profiled companies

A third-party mRNA therapeutics market outlook study released on August 26, 2026, projects continued industry expansion through 2035 and highlights a set of themes the report says are shaping the sector. The study, distributed through Globe Newswire and syndicated by Yahoo Finance, frames growth around expanding oncology and rare-disease pipelines, strategic partnerships, and advances in delivery technologies, which it says are helping broaden the clinical and commercial footprint of mRNA-based medicines.

The report, titled “mRNA Therapeutics Market Outlook Report 2026-2035,” includes company profiles spanning established players and emerging developers. In addition to Moderna, the profile list named Arcturus Therapeutics, BioNTech, CureVac, Providence Therapeutics, RNAimmune, and Recode Therapeutics, among others.

Moderna is specifically included in the study’s company-by-company outlook, reflecting investor and industry attention on how large mRNA platforms are competing not only in vaccine-adjacent areas, but increasingly across oncology and rare disease indications. While the announcement does not provide Moderna-specific pipeline milestones in the material available for this review, it places the company within a broader market narrative centered on modality scaling and platform maturation.

One of the key messages attributed to the report is that the mRNA therapeutics market is being driven by both product development and the supporting “how you deliver it” infrastructure. Delivery technology, in this context, refers to the systems and formulations used to get mRNA into target cells effectively and safely, a factor that can influence efficacy, tolerability, and the practicality of expanding indications. The release ties delivery advances to the expected market growth through 2035.

Strategic partnerships are also listed as a contributor to growth. In mRNA therapeutics, partnerships can cover a range of collaborations, including co-development, technology sharing, and regional commercialization arrangements. The published excerpt does not name specific deals involving Moderna, but it positions partnerships as part of the sector’s go-to-market and development strategy.

The study’s framing suggests that oncology and rare diseases are expected to remain central to how companies differentiate. Oncology often requires multi-factor decision-making around dosing schedules, combination regimens, and patient selection, while rare disease programs can depend on smaller trial populations and more targeted endpoints. The release does not provide trial results or regulatory timelines in the text available here, but it explicitly connects pipeline expansion in these areas to the report’s projected growth.

For Moderna, the practical takeaway from the announcement is not a set of quantified forecasts for the company, but rather its inclusion in a sector-wide outlook that emphasizes platform expansion, delivery progress, and partnering. Readers should treat the report as an external market assessment rather than a corporate update, since the material available for review does not include Moderna guidance, earnings metrics, or new company disclosures tied to specific programs.

What remains unclear from the available material is how the report breaks down expected market share by company, what assumptions it uses for adoption rates, pricing, and regulatory timelines, and whether it cites specific Moderna product milestones during 2026 to 2035. The August 26 release excerpt also does not provide detailed numbers, so the direction and themes are clearer than the underlying magnitude of the forecast.